ClinicalTrials.gg
CompletedNCT06772987Updated Nov 20, 2026Results posted

NQ TMS for MDD Therapy Using 1 Day x 3 Sessions Protocol for Adult Patient

An interventional study of Accelerated rTMS treatment in Major Depressive Disorder (MDD), sponsored by NeuroQore Inc.. Completed at 1 site in United States. Open to participants aged 22 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by NeuroQore Inc. · Not applicable, Interventional, and Treatment

How we know

Updated Nov 20, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
55
Allocation
Not applicable
Ages
22 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,500 studies in Depressive Disorder, Major with a site in United States — 216 open to participants now, 258 under way, 26 of them phase 3. Depressive Disorder, Major · United States.

Enrollment
755th of 1,323
55 · median 70
Started
2025
with 68 others
No phase
472 of 1,500
94 open now
Registered
1,368th of 1,500
by date

Among the 1,500 studies in Depressive Disorder, Major with a site in United States, this one is the 755th largest by enrollment of the 1,323 interventional ones that give a count, is one of 69 that started in 2025, is one of 472 with no phase, and was the 1,368th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

216 of the 1,500 studies in Depressive Disorder, Major with a site in United States are open now. Recruiting first, the newest first:

211 more — sign in →

All 216 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 22 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,500 studies in Depressive Disorder, Major with a site in United States, or all of them as a file.
02

Study summary

Transcranial Magnetic Stimulation (TMS) Therapy is a non-invasive procedure that uses magnetic pulses to stimulate the cortex (brain) to treat Major Depressive Disorder (MDD). Currently established therapy uses one 19-minute treatment session per day for 5 days per week for 6 weeks, for a total of 30 treatment sessions.

The goal of this clinical trial is to evaluate the safety and effectiveness of an accelerated but shortened TMS dosing regimen for adults with MDD aged 22-85.

Participants in this study will be subjected to the same 19-minutes treatment session, but three times on the same day, and only for one day. This will greatly reduce the logistical burden of completing the therapy regime.

Read the detailed description

Study Description:

This single center, open label study will evaluate the safety and efficacy of accelerating the delivery of the NeuroQore TMS system's rectangular waveform rTMS protocol for the treatment of adults with MDD aged 22-85.

Currently cleared protocol with the FDA (the Standard of Care Protocol) is one 19-min treatment session a day for 5 days/week for 6 weeks. The accelerated protocol will involve the same 19-min treatment session offered three times in a single day, with no additional treatment sessions.

Primary Objectives:

  1. To assess the efficacy of the NeuroQore TMS system, with accelerated delivery in the treatment of adults with MDD, as measured by a change in MADRS score 24 hours and 7 days after the treatment end.
  2. To compare the safety profile of the accelerated delivery protocol to the historical safety profile of the Standard of Care protocol.

Endpoints:

Primary

  • Change in MADRS score from baseline to 24 hours and 7 days post-treatment.
  • Number and type of adverse events. Secondary
  • Change in PHQ-9 score from baseline to 24 hours and 7 days post-treatment.

Study Population:

Men and women 22-85 with MDD that have failed one medication in the current episode.

Study Intervention:

NeuroQore TMS System includes (1) a pulse generator, (2) a magnetic coil, (3) a coil cooler, and (4) a chair with a headpiece. It has been cleared for clinical use (K232688) by the FDA for the treatment of MDD using a 19-min Standard of Care protocol.

Treatment during this study will be administered according to this protocol and following the instructions in the device user manual. Personalized stimulation targets will be produced from participants' structural MRI via the proprietary targeting generation component of the NeuroQore TMS system.

Only personnel trained and certified by NeuroQore will be permitted to administer treatment. All session and device information will be captured on appropriate data collection forms.

Study Duration:

The study is anticipated to last up to 6 months including enrollment and follow-up. Individual participant duration in the study will be 1 day of treatment, 24-hour and 7-day follow-up.

03

Conditions studied

  • Major Depressive Disorder (MDD)

Keywords

  • Major Depressive Disorder
  • Accelerated Treatment
  • 1-Day Treatment
04

Who can participate

Ages eligible
22 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females aged 22-85.
  2. Current diagnosis of major depressive disorder according to the criteria defined in the current Diagnosis and Statistical Manual of Mental Disorders () without psychotic features.
  3. Failed to receive satisfactory improvement from prior antidepressant medication in the current episode.
  4. MADRS score > 20 at baseline and immediately prior to the day of treatment.
  5. Agrees to adhere to the study treatment and follow-up schedule.
  6. Willingness to remain on stable medications during rTMS therapy.
  7. Fluent in English.

Exclusion criteria

Exclusion Criteria:

  1. Any medical conditions that would preclude the use of rTMS to treat depression.
  2. Any conditions that would prevent the ability to undergo MRI testing.
  3. Pregnancy as determined by serum/urine pregnancy test
  4. History of epilepsy, seizure(s), or a seizure disorder as determined by the principal investigator based on a medical history obtained from the patient and/or others authorized to provide such history, combined with a brief screening instrument.
  5. Active substance abuse
  6. Diagnosis of bipolar or psychotic disorder
  7. Considered to be at moderate-high risk of suicide according to the CSSRS assessment (i.e., Answers YES to Question 3 and NO to Question 6; or answers YES to Question 4, 5, or 6)
  8. As determined by the Principal Investigator, subjects with cognitive impairment according to either the medical history obtained from the patient and/or a reliable secondary source, or the results of the (MoCA) performed during screening.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    Accelerated Protocol

    1 Day x 3 Sessions treatment protocol, with 60 minutes rest between sessions. Each session is a 19-minutes rTMS treatment.

    Device: Accelerated rTMS treatment

Interventions

  • DeviceAccelerated rTMS treatment

    1 Day x 3 Sessions of 19-minutes rTMS treatment, with 60 minutes rest between sessions.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at 7 Days Post-treatment

    Change in Montgomery-Åsberg Depression Rating Scale (MADRS) total score from baseline (treatment day, pre-treatment) to 7 days post-treatment, calculated as baseline minus 7-day score (positive values indicate improvement). The MADRS is a 10-item clinician-rated scale; total score ranges from 0 to 60, with higher scores indicating more severe depression (worse outcome).

    Time frame: Baseline (treatment day, pre-treatment) and 7 days post-treatment

Secondary outcomes

  1. Change From Baseline in Patient Health Questionnaire-9 (PHQ-9) Total Score at 7 Days Post-treatment

    Change in Patient Health Questionnaire-9 (PHQ-9) total score from baseline (treatment day, pre-treatment) to 7 days post-treatment, calculated as baseline minus 7-day score (positive values indicate improvement). The PHQ-9 is a 9-item self-report scale; total score ranges from 0 to 27, with higher scores indicating more severe depression (worse outcome).

    Time frame: Baseline (treatment day, pre-treatment) and 7 days post-treatment

07

Results

Posted Nov 20, 2026
Limitations and caveats
Open-label, single-arm, single-site pilot study without a sham control; outcome raters were not blinded. Post-treatment scores use all available data (N = 50 of 53). Adverse events were collected by non-systematic enquiry.

Participant flow

Participants were recruited from January to April 2025 at a single community outpatient mental health clinic (LGTC Group, San Jose, California) offering rTMS treatment.

Participant flow — Overall Study
MilestoneAccelerated Protocol
Started53
Completed50
Not completed3
Withdrew: Adverse event2
Withdrew: Device malfunction delayed a session; participant chose to discontinue1

Outcome measures

PrimaryChange From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at 7 Days Post-treatment

Change in Montgomery-Åsberg Depression Rating Scale (MADRS) total score from baseline (treatment day, pre-treatment) to 7 days post-treatment, calculated as baseline minus 7-day score (positive values indicate improvement). The MADRS is a 10-item clinician-rated scale; total score ranges from 0 to 60, with higher scores indicating more severe depression (worse outcome).

Time frame:
Baseline (treatment day, pre-treatment) and 7 days post-treatment
Reported as:
Mean · units on a scale
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at 7 Days Post-treatment
units on a scaleAccelerated Protocol
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at 7 Days Post-treatment25.5 ± 5.4
SecondaryChange From Baseline in Patient Health Questionnaire-9 (PHQ-9) Total Score at 7 Days Post-treatment

Change in Patient Health Questionnaire-9 (PHQ-9) total score from baseline (treatment day, pre-treatment) to 7 days post-treatment, calculated as baseline minus 7-day score (positive values indicate improvement). The PHQ-9 is a 9-item self-report scale; total score ranges from 0 to 27, with higher scores indicating more severe depression (worse outcome).

Time frame:
Baseline (treatment day, pre-treatment) and 7 days post-treatment
Reported as:
Mean · units on a scale
Change From Baseline in Patient Health Questionnaire-9 (PHQ-9) Total Score at 7 Days Post-treatment
units on a scaleAccelerated Protocol
Change From Baseline in Patient Health Questionnaire-9 (PHQ-9) Total Score at 7 Days Post-treatment8.5 ± 5.6

Adverse events

Collected over From the start of treatment through 7 days post-treatment (protocol follow-up); naturalistic clinic follow-up to 90 days post-treatment. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Accelerated Protocol0/53 (0%)0/53 (0%)3/53 (5.7%)
Most frequent other events
Most frequent other events
EventAccelerated Protocol
Application site pain (facial/scalp pain during stimulation)General disorders3/53

Baseline characteristics

Modified intent-to-treat population: all 53 participants who started treatment.

Age, Continuous
Age, Continuous(years)Accelerated Protocol
Mean46.5 ± 14.7
Sex: Female, Male
Sex: Female, Male(Participants)Accelerated Protocol
Female35
Male18
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Accelerated Protocol
White, not Hispanic or Latino43
Asian7
Region of Enrollment
Region of Enrollment(participants)Accelerated Protocol
United States53
08

Study locations

1 site
  • LGTC Group
    San Jose, California 95124, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — De-identified individual participant data will not be made available to other researchers; participant consent under HIPAA and California privacy law did not include external data sharing. Aggregate results are posted on ClinicalTrials.gov and published (Goodman MS et al., Neuromodulation 2026, doi:10.1016/j.neurom.2026.05.007).

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in May 2025, 3 months.

Results were first posted in Nov 2026, 1 year 6 months after primary completion.

Of 40 industry-sponsored interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 36. This study's 3 months is below that.

Counting every sponsor, half of 694 studies reached it within 33 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2025
First posted
Jan 14, 2025
StartActual
Jan 16, 2025
Primary completionActual
May 6, 2025
CompletionActual
May 6, 2025
Results first posted
Nov 20, 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 20, 2026
Enrollment
50→55
Nov 20, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedChange From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at 7 Days Post-treatmentTime frame: From enrollment to final MADRS score assessment within 2 weeks. → Baseline (treatment day, pre-treatment) and 7 days post-treatment
Nov 20, 2026
Documents
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedChange From Baseline in Patient Health Questionnaire-9 (PHQ-9) Total Score at 7 Days Post-treatmentTime frame: From enrollment to final PHQ-9 score assessment within 2 weeks. → Baseline (treatment day, pre-treatment) and 7 days post-treatment
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Results posted
    Enrollment 50→55
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedChange From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at 7 Days Post-treatmentTime frame: From enrollment to final MADRS score assessment within 2 weeks. → Baseline (treatment day, pre-treatment) and 7 days post-treatment
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedChange From Baseline in Patient Health Questionnaire-9 (PHQ-9) Total Score at 7 Days Post-treatmentTime frame: From enrollment to final PHQ-9 score assessment within 2 weeks. → Baseline (treatment day, pre-treatment) and 7 days post-treatment
    + 4 other changes: verification date, responsible party, contact details and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06772987
Lead sponsor
NeuroQore Inc.
Responsible party
Sponsor
First posted
Jan 14, 2025
Start date
Jan 16, 2025
Primary completion
May 6, 2025
Completion
May 6, 2025
Results posted
Nov 20, 2026
Last update
Nov 20, 2026

Study contacts

Karthik Ramgopal, DO
principal investigator · LGTC Group

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion